Transdermal CBD Delivery for ASD and Fragile X Symptoms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for behavioral symptoms of Fragile X Syndrome and Autism Spectrum Disorder (ASD) are inadequate, particularly in reducing anxiety, hyperactivity, and compulsive behaviors, and often come with adverse side effects such as gastrointestinal issues and liver function impairment.
Innovation Solution
Transdermal administration of cannabidiol (CBD) in the form of gels or oils, applied to the skin, which allows for controlled and sustained delivery, reducing the intensity and frequency of adverse events and effectively alleviating behavioral symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for behavioral symptoms of FXS and ASD are used, then behavioral symptoms may be addressed, but adverse side effects such as gastrointestinal issues and liver function impairment occur
Solution Approach 1:
The patent changes the route of administration parameter from oral to transdermal delivery. This parameter change allows CBD to bypass the gastrointestinal tract and liver metabolism, thereby maintaining therapeutic effectiveness while eliminating gastrointestinal side effects and liver function impairment associated with oral administration
Solution Approach 2:
The patent introduces a transdermal delivery system as an intermediary between the CBD and the body. This intermediary system enables CBD to enter the bloodstream through the skin, avoiding direct contact with the gastrointestinal tract and liver, thus preventing the harmful effects while maintaining therapeutic action
2Object-affected harmful factors
If transdermal administration of CBD is used, then adverse events are reduced, but controlled and sustained delivery must be achieved
Solution Approach 1:
The patent segments the delivery system into multiple components including the active ingredient CBD, permeation enhancers to facilitate skin penetration, and controlled release agents to sustain delivery over time. This segmentation allows each component to perform its specific function while achieving the overall goal of controlled and sustained delivery with reduced adverse events
3Reliability
If oral administration of CBD is used, then behavioral symptoms are treated, but gastrointestinal issues and liver function impairment occur
Solution Approach 1:
The patent fundamentally changes the administration route parameter from oral to transdermal. This parameter change redirects the drug delivery pathway to bypass the gastrointestinal tract and liver, thereby maintaining treatment effectiveness for behavioral symptoms while eliminating the generation of gastrointestinal issues and liver function impairment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Transdermal CBD significantly reduces behavioral symptoms in both Fragile X Syndrome and ASD, improving scores on clinical scales like ADAMS and ABC-FXS, with minimal adverse events, and enhancing quality of life.
Implementation Method 1
Transdermal administration of cannabidiol (CBD) in the form of gels or oils, applied to the skin, which allows for controlled and sustained delivery
Data Source
AI summary
The present technology relates to a method of treating one or more behavioral symptoms of autism spectrum disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.